ArticleJournal of diabetes investigation2026
Linagliptin increases the expression of LRP2 independent of Nrf2 in streptozotocin-induced diabetic mice.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
AIMS/
introductionOxidative stress is thought to play a role in the onset and progression of diabetic nephropathy (DN). Nuclear factor erythroid-related factor 2 (Nrf2) is a master regulator of antioxidant and detoxification pathways and provides cellular protection against oxidative stress. This study aimed to examine the antioxidant effects of linagliptin, a dipeptidyl peptidase-4 inhibitor, on DN using streptozotocin (STZ)-induced diabetic Nrf2 knockout (Nrf2KO) mice. MATERIALS AND
methodsSix-week-old male Nrf2KO mice and their wild-type (WT) littermates were intraperitoneally injected with STZ (55 mg/kg) for five consecutive days to induce diabetes (DM) and/or treated with linagliptin (10 mg/kg/day) for 8 weeks. We also investigated the effects of linagliptin and high glucose concentrations on Nrf2-mediated signaling in human renal proximal tubular epithelial cells (HRPTECs) using a NRF2-specific siRNA.
resultsDespite the lack of effect on the pathological changes and higher blood glucose levels, linagliptin reduced urinary albuminuria in diabetic mice. Interestingly, linagliptin increased the expression of NADP(H): quinone oxidoreductase-1 (NQO1) and LRP2 (megalin) in renal proximal tubular cells of WT and Nrf2KO mice, and these effects were accompanied by the activation of the AKT pathway. Linagliptin increased the expression of LRP2 under high glucose conditions through a mechanism independent of NRF2. Finally, an AKT siRNA abolished the stimulatory effects of linagliptin on LRP2 expression in HRPTECs.
conclusionsThese results suggested that linagliptin reduced albuminuria in individuals with DN in an NRF2-independent manner and might exert its effects by upregulating LRP2 expression via the AKT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.